Abstract
The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for todays and the futures portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces.
Current Topics in Medicinal Chemistry
Title: Key Aspects of the Novartis Compound Collection Enhancement Project for the Compilation of a Comprehensive Chemogenomics Drug Discovery Screening Collection
Volume: 5 Issue: 4
Author(s): Pascal Rigollier, Hans- Joerg Roth, Jurg Zimmermann, Karine Malagu, Jurgen Hinrichs, Rudolph Giger, David Orain, Peter Meier, Guido Koch, Friederike Stoll, Edgar Jacoby, Pierre Acklin, Jaroslav Stanek, Caroline Engeloch, Ulrich Schopfer, Benjamin Havill, Kamal Azzaoui, Maxim Popov and Ansgar Schuffenhauer
Affiliation:
Abstract: The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for todays and the futures portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces.
Export Options
About this article
Cite this article as:
Rigollier Pascal, Roth Joerg Hans-, Zimmermann Jurg, Malagu Karine, Hinrichs Jurgen, Giger Rudolph, Orain David, Meier Peter, Koch Guido, Stoll Friederike, Jacoby Edgar, Acklin Pierre, Stanek Jaroslav, Engeloch Caroline, Schopfer Ulrich, Havill Benjamin, Azzaoui Kamal, Popov Maxim and Schuffenhauer Ansgar, Key Aspects of the Novartis Compound Collection Enhancement Project for the Compilation of a Comprehensive Chemogenomics Drug Discovery Screening Collection, Current Topics in Medicinal Chemistry 2005; 5 (4) . https://dx.doi.org/10.2174/1568026053828376
DOI https://dx.doi.org/10.2174/1568026053828376 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Silico Studies Most Employed in the Discovery of New Antimicrobial Agents
Current Medicinal Chemistry Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review
Current Cardiology Reviews Synthesis and Biological Evaluation of 5-benzyl-3-pyridyl-1H-1,2,4-triazole Derivatives as Xanthine Oxidase Inhibitors
Medicinal Chemistry Free ISG15 and Protein ISGylation Emerging in SARS-CoV-2 Infection
Current Drug Targets A New Perspective of Cannabinoid 1 Receptor Antagonists: Approaches Toward Peripheral CB1R Blockers without Crossing the Blood-Brain Barrier
Current Topics in Medicinal Chemistry High Throughput Screening for Drug Discovery and Virus Detection
Combinatorial Chemistry & High Throughput Screening COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail
Infectious Disorders - Drug Targets Studies on Novel Pyridine and 2-pyridone Derivatives of N-arylpiperazine as α-adrenoceptor Ligands
Medicinal Chemistry Design of Novel Phosphopantetheine Adenylyltransferase Inhibitors: A Potential New Approach to Tackle <i>Mycobacterium tuberculosis</i>
Current Topics in Medicinal Chemistry Computational Methods for Remote Homolog Identification
Current Protein & Peptide Science The Role of Hypocarbia in the Development of Cystic Periventricular Leukomalacia
Current Pediatric Reviews Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Protein & Peptide Letters Studies on Chemistry, Spectroscopy and Antioxidant Activities of Chromium(III)-Hydrazide Complexes
Medicinal Chemistry Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Current Pharmaceutical Design Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report
Current HIV Research VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry An Easy Assembled, Click-Generated Macrocyclic Chromoionophores as Mercury(II) Sensors
Letters in Organic Chemistry Dedicated COVID-19 Resource Center in Radiology Journals: Its Citation Metrics and Altmetrics Impact
Current Medical Imaging